English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [5127]
News [14850]
Articles [105]
Editorials [3]
Conferences [245]
elearning [21]
SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant...
Prof Thomas Flaig - University of Colorado Denver, Denver, USA
SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for muscle-invasive bladder cancer ( Prof Thomas Flaig - University of Colorado Denver, Denver, USA )
10 Jun 2019
SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive...
Prof Hope Rugo - University of California, San Francisco, USA
SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC after prior anti-HER2 therapies ( Prof Hope Rugo - University of California, San Francisco, USA )
10 Jun 2019
Preliminary results of earlier steroid use with axicabtagene ciloleucel in...
Prof Max Topp - University of Würzburg, Würzburg, Germany
Preliminary results of earlier steroid use with axicabtagene ciloleucel in patients with R/R large B cell lymphoma ( Prof Max Topp - University of Würzburg, Würzburg, Germany )
6 Jun 2019
Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE)...
Prof Max Topp - University of Würzburg, Würzburg, Germany
Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy in patients with R/R multiple myeloma ( Prof Max Topp - University of Würzburg, Würzburg, Germany )
6 Jun 2019
POLO Trial: Olaparib as a maintenance treatment following first-line...
Dr Teresa Macarulla - Vall d’Hebron Barcelona University Hospital, Barcelona...
POLO Trial: Olaparib as a maintenance treatment following first-line chemotherapy in patients with metastatic pancreatic cancer ( Dr Teresa Macarulla - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain )
6 Jun 2019
Breast cancer highlights from ASCO 2019
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer highlights from ASCO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
6 Jun 2019
Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until...
Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France
Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression in early relapsed refractory multiple myeloma ( Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France )
6 Jun 2019
Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma
Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France
Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma ( Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France )
6 Jun 2019
Proton therapy or photon therapy as part of concurrent chemoradiotherapy for...
Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA
Proton therapy or photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer ( Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA )
6 Jun 2019
Carfilzomib and irinotecan in relapsed small cell lung cancer
Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA
Carfilzomib and irinotecan in relapsed small cell lung cancer ( Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA )
6 Jun 2019
FORTE trial results: KRd with or without transplantation in newly diagnosed...
Dr Francesca Gay - University Hospital City of Health and Science of Turin...
FORTE trial results: KRd with or without transplantation in newly diagnosed myeloma according to risk status ( Dr Francesca Gay - University Hospital City of Health and Science of Turin, Turin, Italy )
6 Jun 2019
Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast...
Dr Zahi Mitri - OHSU Hospital, Portland, USA
Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer ( Dr Zahi Mitri - OHSU Hospital, Portland, USA )
6 Jun 2019
<1...152153154155156...428>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2025 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top